Cargando…

Group III phospholipase A2 downregulation attenuated survival and metastasis in ovarian cancer and promotes chemo-sensitization

BACKGROUND: Aberrant lipogenicity and deregulated autophagy are common in most advanced human cancer and therapeutic strategies to exploit these pathways are currently under consideration. Group III Phospholipase A2 (sPLA2-III/PLA2G3), an atypical secretory PLA2, is recognized as a regulator of lipi...

Descripción completa

Detalles Bibliográficos
Autores principales: Ray, Upasana, Roy, Debarshi, Jin, Ling, Thirusangu, Prabhu, Staub, Julie, Xiao, Yinan, Kalogera, Eleftheria, Wahner Hendrickson, Andrea E., Cullen, Grace D., Goergen, Krista, Oberg, Ann L., Shridhar, Viji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8173968/
https://www.ncbi.nlm.nih.gov/pubmed/34082797
http://dx.doi.org/10.1186/s13046-021-01985-9
_version_ 1783702816040157184
author Ray, Upasana
Roy, Debarshi
Jin, Ling
Thirusangu, Prabhu
Staub, Julie
Xiao, Yinan
Kalogera, Eleftheria
Wahner Hendrickson, Andrea E.
Cullen, Grace D.
Goergen, Krista
Oberg, Ann L.
Shridhar, Viji
author_facet Ray, Upasana
Roy, Debarshi
Jin, Ling
Thirusangu, Prabhu
Staub, Julie
Xiao, Yinan
Kalogera, Eleftheria
Wahner Hendrickson, Andrea E.
Cullen, Grace D.
Goergen, Krista
Oberg, Ann L.
Shridhar, Viji
author_sort Ray, Upasana
collection PubMed
description BACKGROUND: Aberrant lipogenicity and deregulated autophagy are common in most advanced human cancer and therapeutic strategies to exploit these pathways are currently under consideration. Group III Phospholipase A2 (sPLA2-III/PLA2G3), an atypical secretory PLA2, is recognized as a regulator of lipid metabolism associated with oncogenesis. Though recent studies reveal that high PLA2G3 expression significantly correlates with poor prognosis in several cancers, however, role of PLA2G3 in ovarian cancer (OC) pathogenesis is still undetermined. METHODS: CRISPR-Cas9 and shRNA mediated knockout and knockdown of PLA2G3 in OC cells were used to evaluate lipid droplet (LD) biogenesis by confocal and Transmission electron microscopy analysis, and the cell viability and sensitization of the cells to platinum-mediated cytotoxicity by MTT assay. Regulation of primary ciliation by PLA2G3 downregulation both genetically and by metabolic inhibitor PFK-158 induced autophagy was assessed by immunofluorescence-based confocal analysis and immunoblot. Transient transfection with GFP-RFP-LC3B and confocal analysis was used to assess the autophagic flux in OC cells. PLA2G3 knockout OVCAR5 xenograft in combination with carboplatin on tumor growth and metastasis was assessed in vivo. Efficacy of PFK158 alone and with platinum drugs was determined in patient-derived primary ascites cultures expressing PLA2G3 by MTT assay and immunoblot analysis. RESULTS: Downregulation of PLA2G3 in OVCAR8 and 5 cells inhibited LD biogenesis, decreased growth and sensitized cells to platinum drug mediated cytotoxicity in vitro and in in vivo OVCAR5 xenograft. PLA2G3 knockdown in HeyA8MDR-resistant cells showed sensitivity to carboplatin treatment. We found that both PFK158 inhibitor-mediated and genetic downregulation of PLA2G3 resulted in increased number of percent ciliated cells and inhibited cancer progression. Mechanistically, we found that PFK158-induced autophagy targeted PLA2G3 to restore primary cilia in OC cells. Of clinical relevance, PFK158 also induces percent ciliated cells in human-derived primary ascites cells and reduces cell viability with sensitization to chemotherapy. CONCLUSIONS: Taken together, our study for the first time emphasizes the role of PLA2G3 in regulating the OC metastasis. This study further suggests the therapeutic potential of targeting phospholipases and/or restoration of PC for future OC treatment and the critical role of PLA2G3 in regulating ciliary function by coordinating interface between lipogenesis and metastasis. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13046-021-01985-9.
format Online
Article
Text
id pubmed-8173968
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-81739682021-06-03 Group III phospholipase A2 downregulation attenuated survival and metastasis in ovarian cancer and promotes chemo-sensitization Ray, Upasana Roy, Debarshi Jin, Ling Thirusangu, Prabhu Staub, Julie Xiao, Yinan Kalogera, Eleftheria Wahner Hendrickson, Andrea E. Cullen, Grace D. Goergen, Krista Oberg, Ann L. Shridhar, Viji J Exp Clin Cancer Res Research BACKGROUND: Aberrant lipogenicity and deregulated autophagy are common in most advanced human cancer and therapeutic strategies to exploit these pathways are currently under consideration. Group III Phospholipase A2 (sPLA2-III/PLA2G3), an atypical secretory PLA2, is recognized as a regulator of lipid metabolism associated with oncogenesis. Though recent studies reveal that high PLA2G3 expression significantly correlates with poor prognosis in several cancers, however, role of PLA2G3 in ovarian cancer (OC) pathogenesis is still undetermined. METHODS: CRISPR-Cas9 and shRNA mediated knockout and knockdown of PLA2G3 in OC cells were used to evaluate lipid droplet (LD) biogenesis by confocal and Transmission electron microscopy analysis, and the cell viability and sensitization of the cells to platinum-mediated cytotoxicity by MTT assay. Regulation of primary ciliation by PLA2G3 downregulation both genetically and by metabolic inhibitor PFK-158 induced autophagy was assessed by immunofluorescence-based confocal analysis and immunoblot. Transient transfection with GFP-RFP-LC3B and confocal analysis was used to assess the autophagic flux in OC cells. PLA2G3 knockout OVCAR5 xenograft in combination with carboplatin on tumor growth and metastasis was assessed in vivo. Efficacy of PFK158 alone and with platinum drugs was determined in patient-derived primary ascites cultures expressing PLA2G3 by MTT assay and immunoblot analysis. RESULTS: Downregulation of PLA2G3 in OVCAR8 and 5 cells inhibited LD biogenesis, decreased growth and sensitized cells to platinum drug mediated cytotoxicity in vitro and in in vivo OVCAR5 xenograft. PLA2G3 knockdown in HeyA8MDR-resistant cells showed sensitivity to carboplatin treatment. We found that both PFK158 inhibitor-mediated and genetic downregulation of PLA2G3 resulted in increased number of percent ciliated cells and inhibited cancer progression. Mechanistically, we found that PFK158-induced autophagy targeted PLA2G3 to restore primary cilia in OC cells. Of clinical relevance, PFK158 also induces percent ciliated cells in human-derived primary ascites cells and reduces cell viability with sensitization to chemotherapy. CONCLUSIONS: Taken together, our study for the first time emphasizes the role of PLA2G3 in regulating the OC metastasis. This study further suggests the therapeutic potential of targeting phospholipases and/or restoration of PC for future OC treatment and the critical role of PLA2G3 in regulating ciliary function by coordinating interface between lipogenesis and metastasis. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13046-021-01985-9. BioMed Central 2021-06-03 /pmc/articles/PMC8173968/ /pubmed/34082797 http://dx.doi.org/10.1186/s13046-021-01985-9 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Ray, Upasana
Roy, Debarshi
Jin, Ling
Thirusangu, Prabhu
Staub, Julie
Xiao, Yinan
Kalogera, Eleftheria
Wahner Hendrickson, Andrea E.
Cullen, Grace D.
Goergen, Krista
Oberg, Ann L.
Shridhar, Viji
Group III phospholipase A2 downregulation attenuated survival and metastasis in ovarian cancer and promotes chemo-sensitization
title Group III phospholipase A2 downregulation attenuated survival and metastasis in ovarian cancer and promotes chemo-sensitization
title_full Group III phospholipase A2 downregulation attenuated survival and metastasis in ovarian cancer and promotes chemo-sensitization
title_fullStr Group III phospholipase A2 downregulation attenuated survival and metastasis in ovarian cancer and promotes chemo-sensitization
title_full_unstemmed Group III phospholipase A2 downregulation attenuated survival and metastasis in ovarian cancer and promotes chemo-sensitization
title_short Group III phospholipase A2 downregulation attenuated survival and metastasis in ovarian cancer and promotes chemo-sensitization
title_sort group iii phospholipase a2 downregulation attenuated survival and metastasis in ovarian cancer and promotes chemo-sensitization
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8173968/
https://www.ncbi.nlm.nih.gov/pubmed/34082797
http://dx.doi.org/10.1186/s13046-021-01985-9
work_keys_str_mv AT rayupasana groupiiiphospholipasea2downregulationattenuatedsurvivalandmetastasisinovariancancerandpromoteschemosensitization
AT roydebarshi groupiiiphospholipasea2downregulationattenuatedsurvivalandmetastasisinovariancancerandpromoteschemosensitization
AT jinling groupiiiphospholipasea2downregulationattenuatedsurvivalandmetastasisinovariancancerandpromoteschemosensitization
AT thirusanguprabhu groupiiiphospholipasea2downregulationattenuatedsurvivalandmetastasisinovariancancerandpromoteschemosensitization
AT staubjulie groupiiiphospholipasea2downregulationattenuatedsurvivalandmetastasisinovariancancerandpromoteschemosensitization
AT xiaoyinan groupiiiphospholipasea2downregulationattenuatedsurvivalandmetastasisinovariancancerandpromoteschemosensitization
AT kalogeraeleftheria groupiiiphospholipasea2downregulationattenuatedsurvivalandmetastasisinovariancancerandpromoteschemosensitization
AT wahnerhendricksonandreae groupiiiphospholipasea2downregulationattenuatedsurvivalandmetastasisinovariancancerandpromoteschemosensitization
AT cullengraced groupiiiphospholipasea2downregulationattenuatedsurvivalandmetastasisinovariancancerandpromoteschemosensitization
AT goergenkrista groupiiiphospholipasea2downregulationattenuatedsurvivalandmetastasisinovariancancerandpromoteschemosensitization
AT obergannl groupiiiphospholipasea2downregulationattenuatedsurvivalandmetastasisinovariancancerandpromoteschemosensitization
AT shridharviji groupiiiphospholipasea2downregulationattenuatedsurvivalandmetastasisinovariancancerandpromoteschemosensitization